Abarca F, Cologne KG, Francescatti A, Brand MI,
Saclarides TJ. Incisionless laparoscopic total proctocolectomy
with ileal J-pouch anal anastomosis. Am
Surg. 2011;77(7):929-932.

Abern M, Kaufman HL, Latchamsetty K. An
update on TroVax for the treatment of progressive
castration-resistant prostate cancer. Onco Targets
Ther. 2011;4:33-41.

Aghajanian C, Sill MW, Darcy KM, Greer B, Mc-
Meekin DS, Rose PG, Rotmensch J, Barnes MN,
Hanjani P, Leslie KK. Phase II trial of bevacizumab
in recurrent or persistent endometrial cancer: a
Gynecologic Oncology Group study. J Clin Oncol.
2011;29(16):2259-2265.

Arvanitis LD, Gattuso P, Iacusso C. Cytologic features
of granular cell astrocytoma in crush preparations.
Diagn Cytopathol. 2011;39(1):77-79.

Barua A, Bitterman P, Bahr JM, Basu S, Sheiner
E, Bradaric MJ, Hales DB, Luborsky JL, Abramowicz
JS. Contrast-enhanced sonography depicts
spontaneous ovarian cancer at early stages in
a preclinical animal model. J Ultrasound Med.
2011;30(3):333-345.

Baum LG. Burn control, an adipocyte-specific
function for galectin-12. Proc Natl Acad Sci U S A.
2011;108(46):18575-18576.

Bonomi P. Lung cancer: new developments point
the way to reduced mortality. Oncology (Williston
Park). 2011;25(1):82, 84.

Bradaric MJ, Barua A, Penumatsa K, Yi Y, Edassery
SL, Sharma S, Abramowicz JS, Bahr JM,
Luborsky JL. Sphingosine-1 phosphate receptor
(S1p1), a critical receptor controlling human
lymphocyte trafficking, is expressed in hen and
human ovaries and ovarian tumors. J Ovarian Res.
2011;4(1):4.

Cantley RL, Gabrielli E, Montebelli F, Cimbaluk
D, Gattuso P, Petruzzelli G. Ancillary studies in
determining human papillomavirus status of squamous
cell carcinoma of the oropharynx: a review.
Patholog Res Int. 2011;2011:138469.

Chaitankar V, Zhang C, Ghosh P, Gong P, Perkins
EJ, Deng Y. Predictive minimum description length
principle approach to inferring gene regulatory
networks. Adv Exp Med Biol. 2011;696:37-43.

Chen AB, Neville BA, Sher DJ, Chen K, Schrag
D. Survival outcomes after radiation therapy for
stage III non-small-cell lung cancer after adoption
of computed tomography-based simulation. J Clin
Oncol. 2011;29(17):2305-2311.

Chubinskaya S, Otten L, Soeder S, Borgia JA,
Aigner T, Rueger DC, Loeser RF. Regulation of
chondrocyte gene expression by osteogenic protein-
1. Arthritis Res Ther. 2011;13(2):R55.

Cobleigh MA. Other options in the treatment
of advanced breast cancer. Semin Oncol.
2011;38(suppl 2):S11-S116.

Daniels TB, Brown PD, Felten SJ, Wu W, Buckner
JC, Arusell RM, Curran WJ, Abrams RA, Schiff D,
Shaw EG. Validation of EORTC prognostic factors
for adults with low-grade glioma: a report using
intergroup 86-72-51. Int J Radiat Oncol Biol Phys.
2011;81(1):218-224.

Dewdney SB, Benn T, Rimel BJ, Gao F, Saad N, Vedantham
S, Mutch DG, Zighelboim I. Inferior vena
cava filter placement in the gynecologic oncology
patient: a 15-year institutional experience. Gynecol
Oncol. 2011;121(2):344-346.

Dewdney SB, Mani NB, Zuckerman DA, Thaker PH.
Uteroenteric fistula after uterine artery embolization.
Obstet Gynecol. 2011;118(2, pt 2):434-436.

Dewdney SB, Rimel BJ, Thaker PH, Thompson DM
Jr, Schmidt A, Huettner P, Mutch DG, Gao F, Goodfellow
PJ. Aberrant methylation of the X-linked ribosomal
S6 kinase RPS6KA6 (RSK4) in endometrial
cancers. Clin Cancer Res. 2011;17(8):2120-2129.

Diavolitsis VM, Rademaker A, Boyle J, Kang Z, Kiel
K, Mulcahy M, Small W Jr. Change in creatinine
clearance over time following upper abdominal
irradiation: a dose-volume histogram multivariate
analysis. Am J Clin Oncol. 2011;34(1):53-57.

Duan L, Motchoulski N, Danzer B, Davidovich I, Shariat-
Madar Z, Levenson VV. Prolylcarboxypeptidase
regulates proliferation, autophagy, and resistance to
4-hydroxytamoxifen-induced cytotoxicity in estrogen
receptor-positive breast cancer cells. J Biol Chem.
2011;286(4):2864-2876.

Eapen A, Ramachandran A, Pratap J, George
A. Activation of the ERK1/2 mitogen-activated
protein kinase cascade by dentin matrix protein 1
promotes osteoblast differentiation. Cells Tissues
Organs. 2011;194(2-4):255-260.

Fenton JR, Bergeron EJ, Coello M, Welsh RJ,
Chmielewski GW. Feeding jejunostomy tubes
placed during esophagectomy: are they necessary?
Ann Thorac Surg. 2011;92(2):504-511.

Fitchett G, Lyndes KA, Cadge W, Berlinger N,
Flanagan E, Misasi J. The role of professional
chaplains on pediatric palliative care teams: perspectives
from physicians and chaplains. J Palliat Med.
2011;14(6):704-707.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S,
Allison JP, Ascierto PA, Atkins MB, Bartunkova J,
Bergmann L, Berinstein N, Bonorino CC, Borden
E, Bramson JL, Britten CM, Cao X, Carson WE,
Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G,
Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas
C, Grizzi F, Guida M, Hakansson L,
Hege K, Herberman RB, Hodi FS, Hoos A, Huber
C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH,
Kalinski P, Kaufman HL, et al. Defining the critical
hurdles in cancer immunotherapy. J Transl Med.
2011;9(1):214.

Gandhi L, Camidge DR, Ribeiro de Oliveira M,
Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan
EM, Litvinovich E, Hemken PM, Dive C, Enschede
SH, Nolan C, Chiu YL, Busman T, Xiong H,
Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin
CM. Phase I study of Navitoclax (ABT-263), a novel
Bcl-2 family inhibitor, in patients with small-cell
lung cancer and other solid tumors. J Clin Oncol.
2011;29(7):909-916.

Ghods AJ, Muñoz L, Byrne R. Surgical treatment
of cerebellar metastases. Surg Neurol Int.
2011;2:159.

Gielda BT, Marsh JC, Zusag TW, Faber LP, Liptay
M, Basu S, Warren WH, Fidler MJ, Batus
M, Abrams RA, Bonomi P. Split-course chemoradiotherapy
for locally advanced non-small cell
lung cancer: a single-institution experience of 144
patients. J Thorac Oncol. 2011;6(6):1079-1086.

Gielda BT, Mehta P, Khan A, Marsh JC, Zusag
TW, Warren WH, Fidler MJ, Abrams RA,
Bonomi P, Liptay M, Faber LP. Weight gain in
advanced non-small-cell lung cancer patients during
treatment with split-course concurrent chemoradiotherapy
is associated with superior survival.
Int J Radiat Oncol Biol Phys. 2011;81(4):985-991.

Gielda BT, Shah AP, Marsh JC, Smart JP, Bernard
D, Rotmensch J, Griem KL. Helical tomotherapy
delivery of an IMRT boost in lieu of interstitial
brachytherapy in the setting of gynecologic malignancy:
feasibility and dosimetric comparison. Med
Dosim. 2011;36(2):206-212.

Gielda BT, Strauss JB, Marsh JC, Turian JV, Griem
KL. A dosimetric comparison between the supine
and prone positions for three-field intact breast radiotherapy.
Am J Clin Oncol. 2011;34(3):223-230.

Gor N, Patil A. Endoscopic management of
postoperative ileocolonic anastomotic bleeding
by using water submersion. Gastrointest Endosc.
2011;74(3):721-722.

Harrop R, Shingler WH, McDonald M, Treasure P,
Amato RJ, Hawkins RE, Kaufman HL, de Belin J,
Kelleher M, Goonewardena M, Naylor S. MVA-5T4-
induced immune responses are an early marker of
efficacy in renal cancer patients. Cancer Immunol
Immunother. 2011;60(6):829-837.

Hill ME, Li X, Kim S, Campbell A, Culler K,
Bloomston M, Zalupski M, Hejna G, Bekaii-Saab T. A
phase I study of the biomodulation of capecitabine
by docetaxel and gemcitabine (mGTX) in previously
untreated patients with metastatic adenocarcinoma
of the pancreas. Cancer Chemother Pharmacol.
2011;67(3):511-517.

Jimenez A, Fung HC, Christopherson KW
II. Cellular therapies supplement: strategies for
improving transplant efficiency in the context of
cellular therapeutics. Transfusion. 2011;51(suppl
4):125S-137S.

Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D,
Reimann JD, Cobleigh MA, Schmidt M, Langmuir
VK, Hillan KJ, Chen DS, Koeppen H. Impact of
exploratory biomarkers on the treatment effect
of bevacizumab in metastatic breast cancer. Clin
Cancer Res. 2011;17(2):372-381.

Kabaker K, Shell K, Kaufman HL. Vaccines for
colorectal cancer and renal cell carcinoma. Cancer
J. 2011;17(5):283-293.

Karmali R, Kassar M, Venugopal P, Shammo
JM, Fung HC, Bayer R, O’Brien T, Gregory SA.
Safety and efficacy of combination therapy with
fludarabine, mitoxantrone, and rituximab followed
by yttrium-90 ibritumomab tiuxetan and maintenance
rituximab as front-line therapy for patients
with follicular or marginal zone lymphoma. Clin
Lymphoma Myeloma Leuk. 2011;11(6):467-474.

Karmali R, Larson ML, Wooldridge JE, Gregory
SA, O’Brien T, Shammo JM, Bueschel K,
Venugopal P. Granulocyte-macrophage colony
stimulating factor-induced immune priming of
cyclophosphamide, doxorubicin, vincristine, and
prednisone with rituximab chemoimmunotherapy
in previously untreated patients with diffuse large
B-cell lymphoma and mantle cell lymphoma. Leuk
Lymphoma. 2011;52(11):2097-2104.

Kasliwal MK, O’Toole JE. Unique radiologic feature
of spinal plasmacytoma: mini-brain appearance.
Neurol India. 2011;59(3):486-487.

Katz MH, Merchant NB, Brower S, Branda M,
Posner MC, William Traverso L, Abrams RA, Picozzi
VJ, Pisters PW; American College of Surgeons
Oncology Group. Standardization of surgical and
pathologic variables is needed in multicenter trials
of adjuvant therapy for pancreatic cancer: results
from the ACOSOG Z5031 trial. Ann Surg Oncol.
2011;18(2):337-344.

Kidd S, Bueso-Ramos C, Jagan S, Paganessi LA,
Boggio LN, Fung HC, Gregory SA, Christopherson
KW II. In vivo expansion of the megakaryocyte
progenitor cell population in adult CD26-deficient
mice. Exp Hematol. 2011;39(5):580-590.e1.

Kim AW, Batus M, Myint R, Fidler MJ, Basu S,
Bonomi P, Faber LP, Wightman SC, Warren WH,
McIntire M, Arvanitis LD, Gattuso P, Xu X, Liptay
MJ. Prognostic value of xanthine oxidoreductase expression
in patients with non-small cell lung cancer.
Lung Cancer. 2011;71(2):186-190.

Kim AW, Liptay MJ, Bonomi P, Warren WH,
Basu S, Farlow EC, Faber LP. Neoadjuvant chemoradiation
for clinically advanced non-small cell lung
cancer: an analysis of 233 patients. Ann Thorac Surg.
2011;92(1):233-241.

Knezevic I, Predescu D, Bardita C, Wang M, Sharma
T, Keith B, Neamu R, Malik AB, Predescu S.
Regulation of dynamin-2 assembly-disassembly and
function through the SH3A domain of intersectin-
1s. J Cell Mol Med. 2011;15(11):2364-2376.

Levenson VV, Melnikov AA. The MethDet: a technology
for biomarker development. Expert Rev Mol
Diagn. 2011;11(8):807-812.

Li F, Lu Y, Ding M, Napierala D, Abbassi S, Chen Y,
Duan X, Wang S, Lee B, Zheng Q. Runx2 contributes
to murine Col10a1 gene regulation through
direct interaction with its cis-enhancer. J Bone
Miner Res. 2011;26(12):2899-2910.

Li LC, Jayaram S, Ganesh L, Qian L, Rotmensch J,
Maker AV, Prabhakar BS. Knockdown of MADD
and c-FLIP overcomes resistance to TRAIL-induced
apoptosis in ovarian cancer cells. Am J Obstet
Gynecol. 2011;205(4):362.e12-25.

Liggett TE, Melnikov A, Yi Q, Replogle C, Hu W,
Rotmensch J, Kamat A, Sood AK, Levenson V.
Distinctive DNA methylation patterns of cell-free
plasma DNA in women with malignant ovarian
tumors. Gynecol Oncol. 2011;120(1):113-120.

Liggett TE, Melnikov AA, Marks JR, Levenson
VV . Methylation patterns in cell-free plasma DNA
reflect removal of the primary tumor and drug
treatment of breast cancer patients. Int J Cancer.
2011;128(2):492-499.

Luborsky JL, Yu Y, Edassery SL, Jaffar J, Yip YY, Liu
P, Hellstrom KE, Hellstrom I. Autoantibodies to mesothelin
in infertility. Cancer Epidemiol Biomarkers Prev.
2011;20(9):1970-1978.

Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B,
Herman J, Sugar E, Piantadosi S, Cameron JL, Solt
S, Onners B, Tartakovsky I, Choi M, Sharma R, Illei
PB, Hruban RH, Abrams RA, Le D, Jaffee E, Laheru
D. A lethally irradiated allogeneic granulocyte-macrophage
colony stimulating factor-secreting tumor
vaccine for pancreatic adenocarcinoma: a phase II
trial of safety, efficacy, and immune activation. Ann
Surg. 2011;253(2):328-335.

Marsh JC, Godbole R, Diaz AZ, Gielda BT,
Turian JV. Sparing of the hippocampus, limbic
circuit and neural stem cell compartment during
partial brain radiotherapy for glioma: a dosimetric
feasibility study. J Med Imaging Radiat Oncol.
2011;55(4):442-449.

Mohammed N, Grills IS, Wong CY, Galerani AP,
Chao K, Welsh R, Chmielewski G, Yan D, Kestin
LL. Radiographic and metabolic response rates following
image-guided stereotactic radiotherapy for
lung tumors. Radiother Oncol. 2011;99(1):18-22.

Monk BJ, Sill MW, Hanjani P, Edwards R, Rotmensch
J, De Geest K, Bonebrake AJ, Walker JL.
Docetaxel plus trabectedin appears active in recurrent
or persistent ovarian and primary peritoneal
cancer after up to three prior regimens: a phase II
study of the Gynecologic Oncology Group. Gynecol
Oncol. 2011;120(3):459-463.

Moore TV, Clay BS, Ferreira CM, Williams JW,
Rogozinska M, Cannon JL, Shilling RA, Marzo
AL, Sperling AI. Protective effector memory CD4
T cells depend on ICOS for survival. PLoS One.
2011;6(2):e16529.

Mulshine JL, van Klaveren RJ. Lung cancer screening:
what is the benefit and what do we do about
it? Lung Cancer. 2011;71(3):247-248.

Nabhan C, Davis N, Bitran JD, Galvez A, Fried
W, Tolzien K, Foss S, Dewey WM, Venugopal
P. Efficacy and safety of clofarabine in relapsed
and/or refractory non-Hodgkin lymphoma,
including rituximab-refractory patients. Cancer.
2011;117(7):1490-1497.

Ough M, Velasco J, Hieken TJ. A comparative analysis
of core needle biopsy and final excision for breast
cancer: histology and marker expression. Am J Surg.
2011;201(5):692-694.

Paganessi LA, Walker AL, Tan LL, Holmes I, Rich
E, Fung HC, Christopherson KW II. Effective mobilization
of hematopoietic progenitor cells in GCSF
mobilization defective CD26-/- mice through
AMD3100-induced disruption of the CXCL12-
CXCR4 axis. Exp Hematol. 2011;39(3):384-390.

Patel K, Farlow EC, Kim AW, Lee BS, Basu S, Coon
JS, DeCresce D, Thimothy L, Walters KA, Fhied C,
Chang C, Chen SH, Faber LP, Bonomi P, Liptay
MJ, Borgia JA. Enhancement of a multianalyte
serum biomarker panel to identify lymph node
metastases in non-small cell lung cancer with
circulating autoantibody biomarkers. Int J Cancer.
2011;129(1):133-142.

Pratap J, Lian JB, Stein GS. Metastatic bone
disease: role of transcription factors and future
targets. Bone. 2011;48(1):30-36.

Rao RD, Cobleigh MA, Gray R, Graham ML II,
Norton L, Martino S, Budd GT, Ingle JN, Wood
WC. Phase III double-blind, placebo-controlled,
prospective randomized trial of adjuvant tamoxifen
vs. tamoxifen and fenretinide in postmenopausal
women with positive receptors (EB193): an intergroup
trial coordinated by the Eastern Cooperative
Oncology Group. Med Oncol. 2011;28(suppl
1):39-47.

Ravindran S, Gao Q, Ramachandran A, Blond S,
Predescu SA, George A. Stress chaperone GRP-
78 functions in mineralized matrix formation. J
Biol Chem. 2011;286(11):8729-8739.

Regine WF, Winter KA, Abrams R, Safran H, Hoffman
JP, Konski A, Benson AB, Macdonald JS, Rich
TA, Willett CG. Fluorouracil-based chemoradiation
with either gemcitabine or fluorouracil chemotherapy
after resection of pancreatic adenocarcinoma:
5-year analysis of the U.S. Intergroup/RTOG 9704
phase III trial. Ann Surg Oncol. 2011;18(5):1319-
1326.

Rhodes AR. Prognostic usefulness of sentinel
lymph node biopsy for patients who have clinically
node negative, localized, primary invasive
cutaneous melanoma: a Bayesian analysis using
informative published reports. Arch Dermatol.
2011;147(4):408-415.

Rimel BJ, Ferda A, Erwin J, Dewdney SB, Seamon
L, Gao F, DeSimone C, Cotney KK, Huh W,
Massad LS. Cervicovaginal cytology in the detection
of recurrence after cervical cancer treatment.
Obstet Gynecol. 2011;118(3):548-553.

Rummel MJ, Gregory SA. Bendamustine’s
emerging role in the management of lymphoid
malignancies. Semin Hematol. 2011;48(suppl
1):S24-S36.

Salminen EK, Kiel K, Ibbott GS, Joiner MC,
Rosenblatt E, Zubizarreta E, Wondergem J,
Meghzifene A. International Conference on
Advances in Radiation Oncology (ICARO):
outcomes of an IAEA meeting. Radiat Oncol.
2011;6:11.

Schloemer N, Lozovatsky M, McClain R, Kent P.
Sustained remission of Chronic Immune Thrombocytopenic
Purpura with low dose hydroxyurea.
Pediatr Blood Cancer. 2011;57(3):528-529.

Schnur JB, Goldsmith RE. Through her eyes. J
Clin Oncol. 2011;29(30):4054-4056.

Schwartzentruber DJ, Lawson DH, Richards JM,
Conry RM, Miller DM, Treisman J, Gailani F, Riley
L, Conlon K, Pockaj B, Kendra KL, White RL,
Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman
ED, Balkissoon J, Reintgen DS, Kaufman
H, Marincola FM, Merino MJ, Rosenberg SA,Choyke P, Vena D, Hwu P. gp100 peptide vaccine
and interleukin-2 in patients with advanced
melanoma.  N Engl J Med. 2011;364(22):2119-
2127.

Shen H, Maki CG. Pharmacologic activation of
p53 by small-molecule MDM2 antagonists. Curr
Pharm Des. 2011;17(6):560-568.

Sher DJ, Balboni TA, Haddad RI, Norris CM Jr,
Posner MR, Wirth LJ, Goguen LA, Annino D,
Tishler RB. Efficacy and toxicity of chemoradiotherapy
using intensity-modulated radiotherapy
for unknown primary of head and neck. Int J
Radiat Oncol Biol Phys. 2011;80(5):1405-1411.

Sher DJ, Posner MR, Tishler RB, Sarlis NJ, Haddad
RI, Holupka EJ, Devlin PM. Relationship
between radiation treatment time and overall
survival after induction chemotherapy for locally
advanced head-and-neck carcinoma: a subset
analysis of TAX 324. Int J Radiat Oncol Biol Phys.
2011;81(5):e813-e818.

Sher DJ, Thotakura V, Balboni TA, Norris CM Jr,
Haddad RI, Posner MR, Lorch J, Goguen LA, Annino
DJ, Tishler RB. Treatment of oral cavity squamous
cell carcinoma with adjuvant or definitive
intensity-modulated radiation therapy. Int J Radiat
Oncol Biol Phys. 2011;81(4):e215-e222.

Sher DJ, Wee JO, Punglia RS. Cost-effectiveness
analysis of stereotactic body radiotherapy and
radiofrequency ablation for medically inoperable,
early-stage non-small cell lung cancer. Int J Radiat
Oncol Biol Phys. 2011;81(5):e767-e774.

Shersher DD, Hong E, Warren W, Faber LP, Liptay
MJ. Adenocarcinoma in a 40-year-old colonic
interposition treated with Ivor Lewis esophagectomy
and esophagogastric anastomosis. Ann
Thorac Surg. 2011;92(6):e113-e114.

Shersher DD, Vercillo MS, Fhied C, Basu S, Rouhi
O, Mahon B, Coon JS, Warren WH, Faber LP,
Hong E, Bonomi P, Liptay MJ, Borgia JA. Biomarkers
of the insulin-like growth factor pathway
predict progression and outcome in lung cancer.
Ann Thorac Surg. 2011;92(5):1805-1811.

Showalter TN, Winter KA, Berger AC, Regine
WF, Abrams RA, Safran H, Hoffman JP, Benson
AB, Macdonald JS, Willett CG. The influence
of total nodes examined, number of positive
nodes, and lymph node ratio on survival after
surgical resection and adjuvant chemoradiation
for pancreatic cancer: a secondary analysis
of RTOG 9704. Int J Radiat Oncol Biol Phys.
2011;81(5):1328-1335.

Tait DL, Blessing JA, Hoffman JS, Moore KN,
Spirtos NM, Lachance JA, Rotmensch J, Miller DS. A phase II study of gemcitabine (gemzar,
LY188011) in the treatment of recurrent or
persistent endometrial carcinoma: a Gynecologic
Oncology Group study. Gynecol Oncol.
2011;121(1):118-121.

Thiemann S, Baum LG. The road less traveled:
regulation of leukocyte migration across vascular
and lymphatic endothelium by galectins. J Clin
Immunol. 2011;31(1):2-9.

Turner J, Brand MI, Saclarides TJ. Pelvic sepsis
after transanal endoscopic microsurgical excision
of rectal polyps. Am Surg. 2011;77(8):E154-
E155.

Turner J, Myers JA, Titze J, Kaufman HL, Bines
SD. Single-incision laparoscopic surgery for
intra-abdominal metastatic melanoma. Am Surg.
2011;77(8):E164-E165.

Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau
JA, Michelin DP, Mannel RS, Hanjani P, De
Geest K, Godwin AK. A Gynecologic Oncology
Group phase II trial of the protein kinase C-beta
inhibitor, enzastaurin and evaluation of markers
with potential predictive and prognostic value
in persistent or recurrent epithelial ovarian and
primary peritoneal malignancies. Gynecol Oncol.
2011;121(3):455-461.

Vasilevsky NA, Ruby CE, Hurlin PJ, Weinberg
AD. OX40 engagement stabilizes Mxd4 and Mnt
protein levels in antigen-stimulated T cells leading
to an increase in cell survival. Eur J Immunol.
2011;41(4):1024-1034.

Witzig TE, Fishkin P, Gordon LI, Gregory SA,
Jacobs S, Macklis R, McLaughlin P, Press O,
Zelenetz AD. Treatment recommendations for
radioimmunotherapy in follicular lymphoma: a
consensus conference report. Leuk Lymphoma.
2011;52(7):1188-1199.

Xu X, Rao GS, Groh V, Spies T, Gattuso P,
Kaufman HL, Plate J, Prinz RA. Major histocompatibility
complex class I-related chain A/B
(MICA/B) expression in tumor tissue and serum
of pancreatic cancer: role of uric acid accumulation
in gemcitabine-induced MICA/B expression.
BMC Cancer. 2011;11(1):194.

Yang H, Gu J, Zheng Q, Li M, Lian X, Miao J, Jiang
J, Wei W. RPB5-mediating protein is required
for the proliferation of hepatocellular carcinoma
cells. J Biol Chem. 2011;286(13):11865-11874.

Yu Y, Edassery SL, Barua A, Abramowicz
JS, Bahr JM, Hellstrom I, Luborsky JL. The
hen model of human ovarian cancer develops
anti-mesothelin autoantibodies in response to
mesothelin expressing tumors. J Ovarian Res.
2011;4:12.